HomeQuestion

Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?

1 Answers

Mednet Member

Medical Oncology · University of Texas MD Anderson Cancer Center

There is a large prospective phase III study that showed a significant improvement in DFS for veliparib+carbo+ paclitaxel versus carbo+paclitaxel (BROCADE3 study; Dieras V et., PMID 32861273).

Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin? | Mednet